Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer Amid TONMYA Launch

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the promotion of Thomas Englese to the position of Chief Commercial Officer, effective immediately. Englese, who previously served as Executive Vice President of Commercial Operations since September 2024, will now lead all commercial functions, including sales, marketing, market access, and commercial operations for the company's portfolio. This includes TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8 mg), the company's recently approved treatment for fibromyalgia in adults, as well as Zembrace® SymTouch® and Tosymra® for acute migraine.

The promotion comes at a critical time for Tonix as it focuses on the commercial rollout of TONMYA, which represents the first new treatment for fibromyalgia in over 15 years. President and CEO Seth Lederman highlighted Englese's instrumental role in building the company's commercial organization and leading the TONMYA launch. Englese expressed confidence in the company's trajectory, emphasizing efforts to expand access, grow the patient and prescriber base, and increase sales as the TONMYA launch broadens.

The strategic importance of this move lies in Tonix's transition from a development-stage biotech to a fully integrated commercial-stage company. With a commercial infrastructure already supporting its migraine products, Tonix is leveraging its expertise to maximize TONMYA's market potential. The company is also exploring additional indications for TONMYA, including ongoing Phase 2 clinical trials for major depressive disorder and acute stress disorder. Beyond its CNS portfolio, Tonix is advancing immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for prevention of kidney transplant rejection.

Thomas Englese's promotion signals Tonix's commitment to strengthening its commercial leadership as it aims to capture significant market share in the fibromyalgia treatment space. The company's strategic focus on commercial execution is expected to be pivotal in driving revenue growth and establishing TONMYA as a leading therapy. As Tonix continues to expand its product pipeline and commercial footprint, the appointment of a dedicated Chief Commercial Officer underscores its dedication to delivering innovative treatments to patients with high unmet medical needs.